Markus Schirle

This study develops a chemical proteomics platform to investigate covalent neoantigen formation and demonstrates immune cell recruitment through antibody-dependent cellular phagocytosis.

This paper develops stereoselective β-lactone electrophiles to covalently target BTK(C481S) and other kinases, showing enantiomers engage distinct kinome subsets.

This paper introduces TRACERs, small-molecule drugs that silence transcription factors in cancer by recruiting repressor complexes, showing efficacy against ER and AR in breast and prostate cancer.

This paper identifies a sulfinyl aziridine compound that selectively degrades MYC by targeting specific residues in its intrinsically disordered regions, demonstrating the potential of chiral small molecules for targeting undruggable proteins.

The paper introduces two novel readthrough promoters that induce eRF1 degradation, leading to PTC suppression and revealing a new ribosome quality control mechanism.

This paper introduces a method to assess E3 ligase activity against neo-substrates using electrophilic probes, demonstrating its effectiveness with VHL and SPSB2.